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Models of normal physiology and disease are necessary in 
cancer research and clinical practice to optimally exploit the 
available (pre)clinical multi-scale and multi-modality data. 
Relevant models often cover multiple spatio-temporal scales 
and require automated access to heterogeneous and 
confidential data, making their development, validation and 
deployment challenging. 
The CHIC (Computational Horizons in Cancer) [1] project 
develops computational models for the cancer domain, as 
well as tools, services and a secure infrastructure for model 
and data access, and reuse. The architecture is designed to 
support the creation of complex disease models (hyper-
models) by composition of reusable component models (hypo-
models). It aims to provide individualized answers to 
concrete clinical questions by patient-specific 
parametrization of disease-specific hyper-models. 
We introduce the CHIC project and illustrate its approach to 
multi-scale cancer modelling by coupled execution of two 
component models operating on distinct spatial scales: 
- OncoSimulator (OS): a spatially discrete model of cancer 
cell proliferation and treatment effect in function of tumour, 
treatment and patient-specific parameters [2], implemented 
as cellular automaton model, 
- Bio-mechanical Simulator (BMS): a macroscopic continuum 
model of mechanical effects caused by tumour expansion in 
patient-specific anatomy, implemented as finite element 
model, based on [3]. 
Both component models exchange information about the 
spatial distribution of cancer cells and mechanical pressure in 
order to simulate the evolution of tumour volume and shape. 
Latter is achieved by correcting simple spherical growth (OS) 
by mechanically induced growth anisotropy (BMS). Results are 
demonstrated on the clinical example of Glioblastoma 
Multiforme. 
CHIC is working towards an extensible platform for in-silico 
oncology with a set of reusable component models at its 
core, covering sub-cellular, cellular and super-cellular scales. 
Viability of infrastructure and composite hyper-models is 
being evaluated against clinical questions in the treatment of 
Nephroblastoma, Glioblastoma and Non-small Cell Lung 
Cancer. 
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Recent evidence indicates that radiation is potent modulator 
of immune system.  The field of radiation biology and 
immunology is at crossroads in cancer research.  With this 
amalgamation, new clinical trials have emerged combining 
radiation therapy with immune modulating agents.  Through 
this partnership, there is a promise to augment higher 
progression survival benefit than cancer immunotherapy as 
monotherapy. Merger of two fields can generate provocative 
themes that need the minds of basic immunologist to interact 
with radiation biologists to define radiation dose exposure, 
types of radiation, sequencing and dosing of vaccination and 
immune modulation biomarkers.  Further, radiation biologist 
can learn from immunologist on what animal models can be 
utilized for primary and metastatic tumors.   As the synergy 
is happening now between these two fields, there is greater 
focus in developing immune modulating agents for adjuvants 
to radiotherapy of solid tumors.  This area is maturing for 
better understanding of the mechanistic actions of in-situ 
radiation vaccine.  With this advent of advancement, there 
are vast opportunities to understand effects of radiation on 
tumor and normal tissue and how this damage cooperates 
with the host immune activation and injury.  Such 
understanding can lead to identification of immune 
biomarkers that can be utilized in immune monitoring in 
tumor control and potentially synergize with other markers 
of normal tissue damage.  This talk will focus on 
understanding the response of some key components of 
tumor immune microenvironment to radiation such as 
regulatory T-cells and myeloid cells in regulating 
immunogenic tumor cell death. The other focus will include 
how host immune machinery reacts to normal tissue injury 
and further any immune biomarkers can be validated for 
immune monitoring in clinical trials.   
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Heavy and quite expensive afterloaders with iridium sources 
are now widely used for the HDR brachytherapy of tumors. 
The cost of this kind of treatment, as well as the necessity of 
heavily shielded canyons and of special technology of source 
delivery and replacement, makes the brachytherapy with 
iridium sources less widespread. Moreover, the relatively 
hard radiation of iridium-192 often makes damage to healthy 
organs close to a tumor. 
These problems of HDR brachytherapy can be resolved with 
ytterbium sources. Compared to other isotopes used for HDR 
brachytherapy, the isotope Yb-169, having the average 
photon emission energy of 93 KeV, requires a much lighter 
shielding.  For example, the tungsten shield of only 2-3 cm 
makes the HDR therapeutic ytterbium source harmless for the 
personnel. Therefore a source loader with ytterbium sources 
may be a compact and cheap desktop device. Moreover, the 
treatment quality may be significantly improved due to 
ytterbium radiation collimation. In the figure we compare 
two ytterbium dose distributions in water: one behind the 
tungsten layer of 2 mm (lower line) and the other without it. 
It follows form this figure that only 2 mm of tungsten allow 
to effectively collimate the ytterbium source radiation – the 
suppressed dose is 30 times lower! This also means that a 
new cheep and accurate preloader, let’s call it an 
“acculoader”, with a hidden ytterbium source inside can be 
easily manufactured. In this case the target irradiation will 
begin just by the source pushing forward.    
